Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)

NCT03327857 is registered in ClinicalTrials.gov with AltruBio Inc. as lead sponsor.

NCT NCT03327857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03327857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Lead sponsor
AltruBio Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2018
Completion date
December 31, 2022
Enrollment
37 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-refractory acute graft-versus-host disease, treatment-refractory acute graft-versus-host disease